Children's Hospital Colorado

Regenerative Therapy for Hypoplastic Left Heart Syndrome

Heart | March 13, 2019
Diagnosis
Infants diagnosed with hypoplastic left heart syndrome in utero
Age
Stem cell collection at birth; Glenn procedure at 3-6 months old
COMIRB number
18-0837
Compensation
Reimbursement for some travel costs

Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome

Physician researchers at Children’s Hospital Colorado want to learn more about using regenerative medicine (stem cells) as a possible treatment option for a rare congenital heart defect called hypoplastic left heart syndrome (HLHS)

Purpose of the study

The goal of this study is to determine the safety and feasibility of delivering a child’s own stem cells into their heart muscle during a specific type of heart surgery called the Glenn procedure. The Glenn procedure is one of three heart surgeries performed on children born with HLHS.

Research details

In order to qualify for this study, patients must have participated in Mayo Clinic’s umbilical cord blood collection protocol, which is separate from the current study. Stem cells collected from the cord blood will be delivered into the right side of their heart during the Glenn surgery procedure, at approximately 3 to 6 months of age. Study participants will be monitored to determine the viability and safety of using regenerative therapy to treat HLHS.

This study is a partnership between Children’s Colorado and the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome at Mayo Clinic.

Contact

For questions about this study, please contact local principal investigator, James Jaggers, MD:

Phone: 720-777-8016

Email: James.Jaggers@childrenscolorado.org

Learn more about the Heart Institute and the Colorado Fetal Care Center at Children’s Colorado.

PRODWEBSERVER1